文献速递中医内科中药与中成药合理使用

中药辅助治疗卒中后癫痫的系统评价与Meta分析

Efficacy and safety of Chinese herbal medicine in post-stroke epilepsy: a systematic review and meta-analysis.
PubMed 文献 · Front Pharmacol · 2023-11-21

该系统评价纳入23项RCT共1901例卒中后癫痫患者,评价中药联合西药对比西药单药治疗的疗效与安全性。口服或静脉中药联合西药可提高75%应答率和总应答率、缩短发作持续时间、减少癫痫样放电,且不良事件更少;但证据质量因发表偏倚和异质性从低到高不等,需更多高质量RCT验证。

要点

  • 口服中药联合西药较西药单药提高75%应答率、总应答率,缩短发作持续时间。
  • 口服或静脉中药联合西药减少癫痫样放电及受累导联数,不良事件少于西药单药。
  • 50%-75%应答率组间无统计学差异,证据质量低至高质量不等。

核心结论

  • 中药辅助治疗可能对卒中后癫痫有效且安全。
  • 因临床数据质量较差,需更多设计良好的RCT确认上述发现。

研究设计与样本

  • 系统检索8个数据库从建库至2023年10月的卒中后癫痫相关随机临床试验。
  • 纳入23项RCT,涉及1901例卒中后癫痫患者。
  • 采用RoB 2.0评估方法学质量,RevMan 5.3和Stata 15.1进行Meta分析,GRADE评价证据质量。

主要发现

  • 口服中药联合西药较西药单药提高75%应答率(RR 1.46,95%CI 1.31-1.62,p<0.00001)。
  • 口服中药联合西药缩短发作持续时间(MD -1.01,95%CI -1.30至-0.72,p<0.00001)。
  • 口服中药联合西药提高总应答率(RR 1.29,95%CI 1.20-1.37,p<0.00001)。
  • 口服中药联合西药减少癫痫样放电(MD -2.02.46,95%CI -2.64至-1.40,p<0.00001)。
  • 口服中药联合西药减少癫痫样放电受累导联数(MD -3.92,95%CI -5.15至-2.68,p<0.00001)。

关键数值与推荐

  • 静脉中药联合西药较西药单药提高75%应答率(RR 1.39,95%CI 1.24-1.56,p<0.00001)。
  • 静脉中药联合西药提高总应答率(RR 1.29,95%CI 1.20-1.39,p<0.00001)。
  • 静脉中药联合西药减少癫痫样放电(MD -3.92,95%CI -5.15至-2.68,p<0.00001)。
  • 静脉中药联合西药减少癫痫样放电受累导联数(MD -1.82,95%CI -2.62至-1.02,p<0.00001)。
  • 50%-75%应答率口服中药联合西药组RR 1.00(95%CI 0.77-1.29,p=0.98),静脉中药联合西药组RR 0.95(95%CI 0.67-1.33,p=0.75),均无统计学显著差异。

临床怎么用

  • 对卒中后癫痫患者,可考虑在规范西药治疗基础上联合口服或静脉中药辅助治疗。
  • 联合中药可能提高应答率、缩短发作持续时间并减少癫痫样放电,且不良事件较少。
  • 需结合患者具体情况个体化使用,并关注证据质量不等的问题。

局限性

  • 临床数据质量较差。
  • 证据水平因发表偏倚和异质性从低到高不等。
  • 需更多设计良好的RCT确认中药辅助治疗的疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Poststroke epilepsy (PSE) is a common complication of strokes that seriously affects the recovery and quality of life of patients, and effective treatments are needed. Chinese herbal medicine (CHM) adjunctive therapy is a viable treatment option, but current evidence is insufficient to support its efficacy and safety. This study aimed to evaluate the efficacy and tolerability of CHM adjunctive therapy in the treatment of PSE. Methods: A systematic search of eight databases was conducted to identify PSE-related randomized clinical trials from the inception of each database through October 2023. The methodological quality assessment was conducted by RoB 2.0, meta-analysis was conducted by RevMan 5.3 and Stata 15.1, and evidence quality was evaluated by GRADE. Results: Twenty-three RCTs involving 1,901 PSE patients were identified. We found that orally administered CHM plus conventional Western medicine (CWM) was superior to CWM monotherapy in increasing the 75% responder rate (RR 1.46, 95% CI: 1.31 to 1.62, p < 0.00001), decreasing the seizure duration (MD -1.01, 95% CI: -1.30 to -0.72, p < 0.00001), improving total responder rate (RR 1.29, 95% CI: 1.20 to 1.37, p < 0.00001), reducing epileptiform discharges (EDs) (MD -2.02.46, 95% CI: -2.64 to -1.40, p < 0.00001), and decreasing the number of leads involved in epileptiform discharge (MD -3.92, 95% CI: -5.15 to -2.68, p < 0.00001). Furthermore, intravenously administered CHM plus CWM was superior regarding 75% responder rate (RR 1.39, 95% CI: 1.24 to 1.56, p < 0.00001), total responder rate (RR 1.29, 95% CI: 1.20 to 1.39, p < 0.00001), EDs (MD -3.92, 95% CI: -5.15 to -2.68, p < 0.00001), and the number of leads involved in epileptiform discharge (MD -1.82, 95% CI: -2.62 to -1.02, p < 0.00001). However, regarding the 50%-75% responder rate, there was no statistically significant difference between the two groups for either oral (RR 1.00, 95% CI: 0.77 to 1.29, p = 0.98) or injectable CHM (RR 0.95, 95% CI: 0.67 to 1.33, p = 0.75). Both orally administered CHM plus CWM (RR 0.56, 95% CI: 0.35 to 0.90, p = 0.02) and intravenously administered CHM plus CWM (RR 0.64, 95% CI: 0.45 to 0.90, p = 0.010) caused fewer AEs than CWM. Furthermore, the levels of evidence ranged from low to high due to publication bias and heterogeneity. Conclusion: CHM adjuvant therapy may be an effective and safe therapy for PSE. However, due to the poor quality of clinical data, more well-designed RCTs are needed to confirm these findings. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=364356, identifier PROSPERO (CRD42022364356).

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Sun T, Wang K, Li L, et al. Efficacy and safety of Chinese herbal medicine in post-stroke epilepsy: a systematic review and meta-analysis. Front Pharmacol. 2023. PMID: 38074155. doi:10.3389/fphar.2023.1286093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。